èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Cyclerion Therapeutics, Inc. ã¯ãé節ãªäžæ¢ç¥çµç³» (CNS) çŸæ£ã®æ²»çè¬ã®çºèŠãéçºãããã³åååã«åãçµãã§ããŸããå瀟ã®è£œååè£ã«ã¯ãããã³ã³ããªã¢è³ççãä¹³é
žã¢ã·ããŒã·ã¹ãããã³è³åäžæ§çºäœ (MELAS) ããã³è¡ç®¡ç
å€ã䌎ãã¢ã«ããã€ããŒç
(ADv) ã®æ²»çãç®çãšãã第 II çžè©Šéšäžã® CNS æµžéæ§å¯æº¶æ§ã°ã¢ãã«é
žã·ã¯ã©ãŒãŒ (sGC) åºæ¿å€ CY6463ãéç¶èµ€è¡çç (SCD) ã®æ²»çãç®çãšãã第 II çžç ç©¶äžã®çµå£æäžè¡ç®¡å¯æº¶æ§ã°ã¢ãã«é
žã·ã¯ã©ãŒãŒåºæ¿å€ Olinciguatãé§åºçãä¿æãããç³å°¿ç
æ§è
çããã³å¿äžå
šã®æ²»çãç®çãšãã第 II çžè©Šéšäžã®çµå£æäžå
šèº« sGC åºæ¿å€ Praliciguat ãªã©ããããŸããå瀟ã¯2018幎ã«èšç«ãããããµãã¥ãŒã»ããå·ã±ã³ããªããžã«æ¬ç€Ÿã眮ããŠããŸãã